Ji-101

In Stock•Starting at $164 for 50 mg•Purity ≥ 99%

CAS No.	900573-88-8
MDL No.	MFCD26142530
MF	C₂₂H₂₀BrN₅O₂
MW	466.30
InChI Key	ZXBFYBLSJMEBEP-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability
50 mg	99%	$164	In Stock
100 mg	99%	$276	In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	900573-88-8
Product Name	Ji-101

Biological Targets

EPHB4·PDGFRB·KDR

Associated Conditions

malignant colon neoplasm·ovarian cancer·neoplasm

* The information provided here is compiled from public sources and is for reference only.

Ji-101

In Stock•Starting at $164 for 50 mg•Purity ≥ 99%

CAS No.	900573-88-8
MDL No.	MFCD26142530
MF	C₂₂H₂₀BrN₅O₂
MW	466.30
InChI Key	ZXBFYBLSJMEBEP-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability
50 mg	99%	$164	In Stock
100 mg	99%	$276	In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	900573-88-8
Product Name	Ji-101

Biological Targets

EPHB4·PDGFRB·KDR

Associated Conditions

malignant colon neoplasm·ovarian cancer·neoplasm

* The information provided here is compiled from public sources and is for reference only.

Ji-101

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Ji-101

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Ji-101

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats.

A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution study of JI-101, a triple kinase inhibitor.

Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.

Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.

Ji-101

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats.

A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution study of JI-101, a triple kinase inhibitor.

Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.

Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.

Documentation